On this page
Short answer Living with deucravacitinib: what to watch for Common questions Related questions Sources**Most side effects of deucravacitinib (brand name Sotyktu) are mild, and the common ones are upper respiratory infections, cold sores, mouth ulcers, acne, and skin folliculitis.**
Deucravacitinib is a once-daily pill that blocks TYK2 signaling to treat moderate to severe plaque psoriasis. In studies it also raised blood creatine phosphokinase, a muscle enzyme, in some people without causing symptoms. Less common but more serious effects include shingles, other infections that need treatment, and changes in liver enzymes or triglycerides, which is why screening and follow-up labs matter. Unlike older JAK inhibitors, it does not carry a boxed warning, but your clinician still checks you for tuberculosis and hepatitis B or C before you start. Keep vaccines up to date before starting, since live vaccines are not recommended while you take it.
Living with deucravacitinib: what to watch for
Common questions
What are the side effects of Deucravacitinib?
Deucravacitinib (Sotyktu) is a TYK2 inhibitor taken as a daily pill for plaque psoriasis. The most commonly reported side effects are upper respiratory infections, raised blood creatine phosphokinase, cold sores, mouth ulcers, acne, and folliculitis. These are usually mild and often settle as treatment continues. Less often it can bring on shingles, an infection that needs antibiotics or antivirals, or shifts in liver enzymes and triglycerides, so clinicians screen for tuberculosis and hepatitis before you start and recheck labs during treatment. Call your clinician for fever, a cough that will not clear, a painful blistering rash in a band, or yellowing of the eyes or skin.